Downregulation of P38 Phosphorylation Correlates with Low-grade Differentiation and Proliferation of Lung Squamous Cell Carcinoma

Overview

Journal Am J Transl Res

Specialty General Medicine

Date 2017 May 5

PMID 28469797

Citations 1

Authors

Yandong Nan

Ruijing Chang

Hua Jiang

Shuanying Yang

Faguang Jin

Yonghong Xie

Affiliations

Soon will be listed here.

Abstract

Background: P38MAPK has been investigated as a tumor-related signaling molecule because of its apparent association with tumorigenesis. This study aimed to investigate P38MAPK expression and its role in lung squamous carcinoma (LSCC).

Methods: The expression of P38MAPK and phosphorylated P38 (P-P38) in LSCC tissues and cells was examined by Western blot, real-time PCR, and immunohistochemistry. The influence of P38MAPK inhibitor SB203580 on the proliferation of LSCC cells was detected by MTT and flow cytometry.

Results: The expression of P-P38 in LSCC tissues and cells was lower than that in cancer-adjacent normal tissues and normal bronchial epithelial cells (P<0.05). In addition, the expression of P-P38 was downregulated in LSCC tissues of poor differentiation, stages III and IV, and with lymph node metastasis compared with the LSCC tissues of well differentiation, stages I and II, and without lymph node metastasis (P<0.05). Moreover, the cell proliferation of LSCC SK-MES-1 cells treated by P38MAPK inhibitor SB203580 significantly increased in a concentration-dependent manner compared with that of SK-MES-1 cells without SB203580 (P<0.05). The inhibition of P38MAPK promoted the transition of the S phase to the G2 phase.

Conclusions: P-P38 was poorly expressed in LSCC tissues and cells. Its low expression was correlated with low-grade differentiation, lymph node metastasis, and advanced stage of LSCC. Inhibition of P38MAPK expression could significantly increase the proliferation of LSCC cells by promoting the transition of the S phase to the G2 phase.

Citing Articles

Comprehensive analysis reveals COPB2 and RYK associated with tumor stages of larynx squamous cell carcinoma.

Zhou G, Zhang S, Jin M, Hu S BMC Cancer. 2022; 22(1):667.

PMID: 35715770 PMC: 9206315. DOI: 10.1186/s12885-022-09766-z.

References

Ji C, Ren F, Ma H, Xu M . The roles of p38MAPK and caspase-3 in DADS-induced apoptosis in human HepG2 cells. J Exp Clin Cancer Res. 2010; 29:50. PMC: 2890544. DOI: 10.1186/1756-9966-29-50. View

Patel N, Sharon C, Baranwal S, Boothello R, Desai U, Patel B . Heparan sulfate hexasaccharide selectively inhibits cancer stem cells self-renewal by activating p38 MAP kinase. Oncotarget. 2016; 7(51):84608-84622. PMC: 5356685. DOI: 10.18632/oncotarget.12358. View

Lu C, Chen H, Shan Z, Yang L . Identification of differentially expressed genes between lung adenocarcinoma and lung squamous cell carcinoma by gene expression profiling. Mol Med Rep. 2016; 14(2):1483-90. PMC: 4940109. DOI: 10.3892/mmr.2016.5420. View

Kittipatarin C, Li W, Bulavin D, Durum S, Khaled A . Cell cycling through Cdc25A: transducer of cytokine proliferative signals. Cell Cycle. 2006; 5(9):907-12. DOI: 10.4161/cc.5.9.2693. View

Coulthard L, White D, Jones D, McDermott M, Burchill S . p38(MAPK): stress responses from molecular mechanisms to therapeutics. Trends Mol Med. 2009; 15(8):369-79. PMC: 3016890. DOI: 10.1016/j.molmed.2009.06.005. View

Lindqvist A, Kallstrom H, Rosenthal C . Characterisation of Cdc25B localisation and nuclear export during the cell cycle and in response to stress. J Cell Sci. 2004; 117(Pt 21):4979-90. DOI: 10.1242/jcs.01395. View

Marzi L, Combes E, Vie N, Ayrolles-Torro A, Tosi D, Desigaud D . FOXO3a and the MAPK p38 are activated by cetuximab to induce cell death and inhibit cell proliferation and their expression predicts cetuximab efficacy in colorectal cancer. Br J Cancer. 2016; 115(10):1223-1233. PMC: 5104890. DOI: 10.1038/bjc.2016.313. View

Weeden C, Solomon B, Asselin-Labat M . FGFR1 inhibition in lung squamous cell carcinoma: questions and controversies. Cell Death Discov. 2016; 1:15049. PMC: 4979434. DOI: 10.1038/cddiscovery.2015.49. View

Biaoxue R, Shuanying Y, Wei L, Wei Z, Zongjuan M . Maintenance therapy of gefitinib for non-small-cell lung cancer after first-line chemotherapy regardless of epidermal growth factor receptor mutation: a review in Chinese patients. Curr Med Res Opin. 2012; 28(10):1699-708. DOI: 10.1185/03007995.2012.728525. View

10.

Koul H, Pal M, Koul S . Role of p38 MAP Kinase Signal Transduction in Solid Tumors. Genes Cancer. 2013; 4(9-10):342-59. PMC: 3863344. DOI: 10.1177/1947601913507951. View

11.

Greenberg A, Basu S, Hu J, Yie T, Rom W, Lee T . Selective p38 activation in human non-small cell lung cancer. Am J Respir Cell Mol Biol. 2002; 26(5):558-64. DOI: 10.1165/ajrcmb.26.5.4689. View

12.

Nan Y, Yang S, Tian Y, Zhang W, Zhou B, Bu L . Analysis of the expression protein profiles of lung squamous carcinoma cell using shot-gun proteomics strategy. Med Oncol. 2008; 26(2):215-21. DOI: 10.1007/s12032-008-9109-4. View

13.

Cuadrado A, Nebreda A . Mechanisms and functions of p38 MAPK signalling. Biochem J. 2010; 429(3):403-17. DOI: 10.1042/BJ20100323. View

14.

Ambrosino C, Nebreda A . Cell cycle regulation by p38 MAP kinases. Biol Cell. 2001; 93(1-2):47-51. DOI: 10.1016/s0248-4900(01)01124-8. View

15.

Rong B, Zhao C, Liu H, Ming Z, Cai X, Gao W . Elevated serum annexin A1 as potential diagnostic marker for lung cancer: a retrospective case-control study. Am J Transl Res. 2014; 6(5):558-69. PMC: 4212930. View

16.

Tan X, Liao L, Wan Y, Li M, Chen S, Mo W . Downregulation of selenium-binding protein 1 is associated with poor prognosis in lung squamous cell carcinoma. World J Surg Oncol. 2016; 14:70. PMC: 4782367. DOI: 10.1186/s12957-016-0832-6. View

17.

Liu Z, Zheng Q, Chen W, Wu M, Pan G, Yang K . Chemosensitizing effect of Paris Saponin I on Camptothecin and 10-hydroxycamptothecin in lung cancer cells via p38 MAPK, ERK, and Akt signaling pathways. Eur J Med Chem. 2016; 125:760-769. DOI: 10.1016/j.ejmech.2016.09.066. View

18.

Rong B, Zhao C, Gao W, Yang S . Matrine promotes the efficacy and safety of platinum-based doublet chemotherapy for advanced non-small cell lung cancer. Int J Clin Exp Med. 2015; 8(9):14701-17. PMC: 4658841. View

19.

Biaoxue R, Xiling J, Shuanying Y, Wei Z, Xiguang C, Jinsui W . Upregulation of Hsp90-beta and annexin A1 correlates with poor survival and lymphatic metastasis in lung cancer patients. J Exp Clin Cancer Res. 2012; 31:70. PMC: 3444906. DOI: 10.1186/1756-9966-31-70. View